London City Equities Limited

LCE

London City Equities Ltd. is a holding company. The company is headquartered in Sydney, New South Wales. The firm is focused on investing in entities that have market shares and offer inherent growth. Its segments include Equity Investment and Other. The company is a selective company-centric investor and not a broad market follower. Its investment strategy is to invest long term in strategic shareholdings in companies, which hold industry positions.

LCL Resources Limited

LCL

Los Cerros Ltd. operates as a mineral exploration, mining, and development company. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-05-18. The firm is focused on exploration in two countries, Papua New Guinea (PNG) and Colombia. Its Quinchia Gold Project is located in central west Colombia, 100 kilometers (km) south of Medellin, in the department of Risaralda, and 70km south of the Company’s Andes Gold Project, the 10,500 hectares (ha) Quinchia Gold Project is part of the Mid-Cauca Gold belt which hosts many multi-million-ounce discoveries. Its Andes Gold Project is located in Antioquia, Risaralda, and Choco, Departments of Colombia. Its Ono Project consists of 1,630 square kilometers (km2) of granted contiguous exploration licenses. The company is situated approximately 150km from the industrial port of Lae and within the same structural belt as the Hidden Valley gold mine and the Wafi-Golpu copper/gold project. Its Veri Veri prospect is situated approximately 100km ESE of Port Moresby and 50km NE of Kupiano port.

LBT Innovations Limited

LBT

LBT Innovations Ltd. is an Australian developer of clinical and diagnostic technology, which has emerged as a groundbreaking designer of advanced automated solutions for the preparation and analysis of microbiology culture specimens, with significant benefits for busy clinical laboratories. The company is headquartered in Adelaide, South Australia and currently employs 40 full-time employees. The company went IPO on 2006-07-31. Its principal activities includes researching, developing, and commercializing technologies for the healthcare and laboratory supply markets. Its capabilities include artificial intelligence (AI), image analysis and software engineering solutions that improve medical diagnostic workflows. Its Automated Plate Assessment System (APAS) is a platform technology that automates culture-plate screening and interpretation. Its products include APAS Independence and APAS Analysis Modules. The APAS Independence combines AI, software and imaging analysis to create a platform technology for intelligent image interpretation. The APAS Analysis Modules are the intelligent image analysis software that works together with the APAS Independence to enable the screening of microbiology culture plates. Its pipeline includes APAS- antimicrobial resistance (AMR) Analysis Module, Automated Gram Stain Assessment, Biofilm, MicroStreak and WoundVue.